Back to blog
March 2, 2025
Biologics in Non-Radiographic Axial Spondyloarthritis: Effects and Response Patterns
Non-radiographic axial spondyloarthritis (nr-AxSpA) is a subtype of axial spondyloarthritis characterized by the absence of visible changes on X-ray or MRI, and often normal levels of inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). This condition can be challenging to treat, especially when traditional markers of inflammation are not elevated. Biologics have emerged as a treatment option, but their effectiveness in patients with normal CRP/ESR levels remains a topic of interest.
Biologics and Their Effects on nr-AxSpA
Biologics, particularly tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors, have been used to treat nr-AxSpA. Studies have shown that biologics can be effective even in patients with normal CRP/ESR levels, although the response may vary. For instance, a study on etanercept, a TNFi, indicated that baseline CRP levels could predict a positive response to treatment, but significant improvements were also observed in patients with normal CRP levels The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis.
Another study highlighted that certolizumab pegol, another TNFi, provided substantial improvements in nr-AxSpA patients regardless of their baseline MRI and CRP status, suggesting that biologics can be beneficial even when traditional inflammatory markers are not elevated Certolizumab Pegol Efficacy in Patients With Non�Radiographic Axial Spondyloarthritis.
Patterns in Treatment Response
The response to biologics in nr-AxSpA patients with normal CRP/ESR levels can be influenced by several factors. A study from the British Society for Rheumatology Biologics Register found that socioeconomic factors, mental health, and comorbidities could predict non-response to biologic therapies Predicting non-response to biologic therapy amongst patients with axSpA.
Moreover, a cross-sectional study in the United States revealed frequent switching of biologics among nr-AxSpA patients, primarily due to inefficacy, with common reasons being condition worsening and loss of response Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis.
Clinical Implications
The findings suggest that while biologics can be effective for nr-AxSpA patients with normal CRP/ESR levels, the response is not uniform across all patients. Clinicians should consider individual patient characteristics, including baseline inflammatory markers, socioeconomic factors, and mental health, when predicting treatment outcomes. Additionally, the potential need for switching biologics should be anticipated in cases of inadequate response.
Conclusion
Biologics offer a promising treatment avenue for nr-AxSpA patients, even those with normal CRP/ESR levels. However, the variability in response highlights the need for personalized treatment strategies. Further research is needed to better understand the predictors of response and to optimize treatment regimens for this patient population.
This article was generated using artificial intelligence. While we strive for accuracy and include sources, it can make mistakes. Check important info and always consult a healthcare professional for medical advice.